Evidence map›Paper›PMID 41801644›Full record

Trial reportClinical pharmacokinetics2026

Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods.

Félicien Le Louedec, Laura Morvan, Loïc Mourey, Maud Maillard, Christelle Vachoux, Malika Yakoubi, Diego Tosi, Gwenaelle Gravis, Guilhem Roubaud, Frédéric Thuillier and 5 more

Registry-linked trialAbstract readClinical Trial, Phase IVMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02555748 (Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02555748 phase4completednot on this map

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

TypeinterventionalSponsorInstitut Claudius RegaudRan2015 to 2020Enrolled47ConditionsMetastatic Renal Cell CancerArmsPazopanib, Sunitinib
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Félicien Le LouedecUniv Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France.
Laura MorvanUniv Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France.
Loïc MoureyDepartment of Medical Oncology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France.
Maud MaillardUniv Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France.
Christelle VachouxUniv Toulouse, Inserm, CRCT, Toulouse, France.
Malika YakoubiUniv Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France.
Diego TosiIRCM, Montpellier, France.
Gwenaelle GravisDepartment of Medical Oncology, Institut Paoli Calmettes, Aix Marseille Univ, INSERM, CNRS, CRCM, Marseille, France.
Guilhem RoubaudDepartment of Medical Oncology, Institut Bergonié, Bordeaux, France.
Frédéric ThuillierCHU Limoges, Limoges, France.
Helen BoyleDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
Fabienne ThomasUniv Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France.
Mélanie White-KoningUniv Toulouse, Inserm, CRCT, Toulouse, France.
Florent PuissetUniv Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France.
Étienne ChatelutUniv Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France. Chatelut.Etienne@iuct-oncopole.fr.ORCID 0000-0002-7740-9096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesTherapeutic drug monitoring of protein kinase inhibitors (PKIs) usually relies on the measure of a single trough concentration at steady-state (C

methodsConcentration data from 41 renal cancer patients included in the SUP-R trial (NCT02555748) measured 2 and 6 hours after an intake were analyzed (MAP-Bayesian estimation of PK parameters) in order to predict C

resultsThe quality of C

conclusionThe benefit of the model-averaging method for the model-informed precision dosing of sunitinib and pazopanib is likely applicable to other protein kinase inhibitors. Thanks to 'mapbayr', this framework was implemented as a standalone shiny application to be used in clinical settings.

Indexed as

Kidney NeoplasmsModels, BiologicalProtein Kinase InhibitorsPyrimidinesSulfonamidesAntineoplastic AgentsBayes TheoremDrug MonitoringFemaleHumansIndazolesMalePrecision MedicineSunitinibAntineoplastic AgentsIndazolespazopanibProtein Kinase InhibitorsPyrimidinesSulfonamidesSunitinib

Identifiers

PMID41801644
PMCPMC13183724

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.